Welcome to our dedicated page for Embecta news (Ticker: EMBC), a resource for investors and traders seeking the latest updates and insights on Embecta stock.
Embecta Corp. (EMBC) generates a steady stream of news as a global diabetes care and medical supplies company listed on The Nasdaq Global Select Market. The company describes itself as advancing a 100-year legacy in insulin delivery and working to transform from an insulin delivery company into a broader medical supplies company. News about embecta often reflects this strategic evolution and its role in diabetes care worldwide.
Investors and observers can expect frequent updates tied to financial performance, including quarterly and full-year earnings results. embecta regularly issues press releases detailing revenues by geography and product family, operating margins, adjusted metrics, and guidance for upcoming fiscal years. These announcements are often accompanied by commentary on business drivers such as product volumes, pricing, foreign currency effects, and contract manufacturing activity.
Another key category of news covers strategic initiatives and partnerships. embecta has highlighted its global ERP implementation, brand transition from BD-branded to embecta-branded injection devices, and restructuring efforts aimed at improving profitability and reducing debt. The company also reports on collaborations with pharmaceutical partners to co-package embecta pen needles with potential generic GLP-1 therapies, as well as humanitarian partnerships, including large-scale donations of pen needles and insulin syringes through organizations such as Direct Relief.
embecta’s news flow also includes corporate governance and capital allocation topics, such as board changes, upcoming investor conferences, and regular announcements of quarterly cash dividends. Together, these updates provide insight into how embecta manages its diabetes-focused portfolio, pursues growth opportunities, and communicates with stockholders. For readers tracking EMBC, this news page offers an organized view of the company’s financial disclosures, strategic milestones, and corporate developments over time.
The Board of Directors of Embecta Corp. (NASDAQ: EMBC) has announced a quarterly cash dividend of $0.15 per share, set to be paid on January 11, 2023. This dividend will be distributed to stockholders registered by the close of business on December 30, 2022. Embecta, a leading diabetes care company, leverages nearly a century of experience in insulin delivery to improve the lives of people living with diabetes.
Embecta Corp. (NASDAQ: EMBC) has announced its participation in the upcoming J.P. Morgan Healthcare Conference on January 11, 2023, at 9:45 a.m. PT / 12:45 p.m. ET. The company, known for its significant role in diabetes care, previously operated under Becton, Dickinson and Company. Interested parties can access audio webcasts of the presentation through the Company’s investor relations website. With nearly 100 years in insulin delivery, Embecta aims to enhance the lives of individuals with diabetes through innovative solutions and a dedicated workforce of over 2,000 employees worldwide.
Embecta Corp. (EMBC) and Intuity Medical announced a co-promotional agreement to market the POGO Automatic® Blood Glucose Monitoring System across the U.S., effective immediately. Embecta, a leader in diabetes care following its spin-off from BD, aims to enhance diabetes management solutions with this innovative device. POGO Automatic simplifies blood glucose testing using a 10-test cartridge technology, making it the only FDA-cleared automatic blood glucose monitor. This partnership expands Embecta's offerings while supporting Intuity's mission to improve diabetes care.
Embecta Corp. (Nasdaq: EMBC) announced it will host a conference call on December 20, 2022, at 8:00 a.m. ET to discuss its fiscal Q4 and full-year 2022 financial results, along with preliminary guidance for fiscal year 2023. As a leading diabetes care company, Embecta aims to leverage its nearly 100-year expertise in insulin delivery to enhance life quality for diabetes patients. The call will discuss significant operational updates, and a replay will be available post-call on their investor relations website.
Embecta Corp. (Nasdaq: EMBC) celebrated National Diabetes Awareness Month by ringing the Nasdaq Opening Bell on November 1, 2022. The event involved advocacy and professional groups focused on improving diabetes care. CEO Devdatt Kurdikar emphasized the importance of education and resources for those living with diabetes. The milestone also marks 100 years since the first successful insulin injection, highlighting the estimated 537 million people living with diabetes globally, many unaware of their condition.
Embecta Corp. (Nasdaq: EMBC) announced participation in two investor conferences in September 2022. The company will take part in a fireside chat at the 2022 Wells Fargo Healthcare Conference on September 8 at 8:00 a.m. ET in Boston, MA. Additionally, it will engage in a fireside chat at the 20th Annual Global Healthcare Conference on September 13 at 2:55 p.m. ET in New York, NY. Audio webcasts of these events will be available on the investor relations section of the company's website.
Embecta Corp. (Nasdaq: EMBC) reported its Q3 and 9-month fiscal 2022 results, revealing revenues of $291.1 million, a 1.3% decline year-over-year. In contrast, constant currency revenue increased by 2.0%. U.S. revenue grew by 4.1% while international revenue fell by 7.1%. Net income dropped to $62.4 million from $104.7 million in the previous year. Adjusted EBITDA was $117.9 million (40.5% margin), lower than last year. The company raised its second-half guidance for constant currency revenue growth and margins, while declaring a $0.15 quarterly dividend.
Embecta Corp. (NASDAQ: EMBC) has declared a quarterly cash dividend of $0.15 for each share of its common stock. This dividend will be paid on September 14, 2022 to stockholders of record as of August 26, 2022. As a leading pure-play diabetes care company, Embecta aims to support individuals with diabetes through innovative solutions, leveraging nearly a century of experience in insulin delivery.
Embecta Corp. (NASDAQ: EMBC) announced it will report its third-quarter financial results for fiscal year 2022 on August 15, 2022. The company’s management will hold a conference call at 8:00 a.m. ET to discuss results and provide an operational update. Embecta is positioned as a significant player in diabetes care following its spin-off from Becton, Dickinson and Company on April 1, 2022. The live webcast of the call will be accessible through the company’s investor relations website.
Embecta Corp. (Nasdaq: EMBC) reported Q2 2022 revenues of $274.5 million, a decline of 3.4% year-over-year. U.S. revenues dropped 5.8%, while international revenues saw a slight decrease of 0.8%. Net income was $79.6 million, down from $107.9 million in Q2 2021. Gross profit margin rose to 69.7%. For the first half of 2022, total revenue was $563.8 million, down 1.0%, with a net income of $178.4 million. The company anticipates a significant revenue decrease of about 7% for the second half of FY 2022, projecting revenues around $555 million due to continuing supply chain challenges.
FAQ
What is the current stock price of Embecta (EMBC)?
What is the market cap of Embecta (EMBC)?
